SCHEMBL1099741

SCHEMBL1099741

Cc1c(N(CCC(F)(F)F)S(C)(=O)=O)sc2ccccc12

nearest known ligand 0.44

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
TRPM8 Q7Z2W7 5/20 0.44
HSD11B1 P28845 1/20 0.36
RORC P51449 1/20 0.34
GRIN1 Q05586 1/20 0.34
ESR1 P03372 1/20 0.34
ESR2 Q92731 1/20 0.34
LMNA P02545 1/20 0.32
TP53 P04637 1/20 0.32
PRNP P04156 1/20 0.32
RXFP1 Q9HBX9 1/20 0.32
NR1H2 P55055 1/20 0.31
ALDH1A1 P00352 2/20 0.31
ATM Q13315 1/20 0.30
PER2 O15055 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1099130 0.89 TRPM8 (0.43) TRPM8HSD11B1RORCGRIN1ESR1
SCHEMBL1098884 0.88 TRPM8 (0.43) TRPM8HSD11B1RORCESR1ESR2
SCHEMBL1100499 0.86 TRPM8 (0.53) TRPM8HSD11B1RORCESR1ESR2
SCHEMBL1097930 0.82 TRPM8 (0.45) TRPM8HSD11B1RORCESR1ESR2
SCHEMBL1099760 0.82 TRPM8 (0.39) TRPM8HSD11B1ESR1ATMPER2
SCHEMBL1100043 0.81 TRPM8 (0.41) TRPM8HSD11B1LMNATP53
SCHEMBL1099514 0.81 TRPM8 (0.41) TRPM8HSD11B1LMNATP53
SCHEMBL1107234 0.80 TRPM8 (0.48) TRPM8RORCESR1ESR2NR1H2
SCHEMBL1100689 0.80 TRPM8 (0.67) TRPM8RORCESR1ESR2
SCHEMBL1099500 0.80 TRPM8 (0.41) TRPM8HSD11B1PRNPRXFP1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9434711-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, N.V. (BE) 2016-09-06 US disclosed
US-20140315899-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2014-10-23 US disclosed
US-8809327-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2014-08-19 US disclosed
EP-2183239-B1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2012-08-22 EP disclosed
US-20120190674-A1 SULFONAMIDES AS TRPM8 MODULATORS BRANUM SHAWN T (US) 2012-07-26 US disclosed
US-8153682-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2012-04-10 US disclosed
US-20090264474-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2009-10-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120190674-A1 SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 TRPM8 1/4885HSD11B1 4304/4885RORC 3514/4885
US-20140315899-A1 SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 TRPM8 1/4885HSD11B1 4304/4885RORC 3514/4885
US-20090264474-A1 SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 TRPM8 1/4885HSD11B1 4304/4885RORC 3514/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.